HCVerso1 and 2: faldaprevir with deleobuvir (BI 207127) and ribavirin for treatment-naïve patients with chronic hepatitis C virus genotype-1b infection

The interferon-free combination of once-daily faldaprevir 120 mg, twice-daily deleobuvir 600 mg, and weight-based ribavirin was evaluated in two Phase III studies (HCVerso1, HCVerso2) in hepatitis C virus genotype-1b-infected, treatment-naïve patients, including those ineligible for peginterferon (H...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Exp Gastroenterol
Autors principals: Sarrazin, Christoph, Castelli, Francesco, Andreone, Pietro, Buti, Maria, Colombo, Massimo, Pol, Stanislas, Calinas, Filipe, Puoti, Massimo, Olveira, Antonio, Shiffman, Mitchell, Stern, Jerry O, Kukolj, George, Roehrle, Michael, Aslanyan, Stella, Deng, Qiqi, Vinisko, Richard, Mensa, Federico J, Nelson, David R
Format: Artigo
Idioma:Inglês
Publicat: Dove Medical Press 2016
Matèries:
Clinical Trial Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5125810/
https://ncbi.nlm.nih.gov/pubmed/27920566
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEG.S111116
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars